Taser defends safety of guns

In a file photo, Steve Tuttle, director of communications for Taser International Inc., holds the X26c stun gun. (Associated Press / The Spokesman-Review)
Associated Press

SCOTTSDALE, Ariz. — Stun gun maker Taser International Inc. on Friday said an independent study found that its stun guns had little effect on the heart functions of humans.

Shares of Taser, which have declined since the start of the year on controversy over the safety of its products, rose 18 cents to close at $11.38 in Friday trading on the Nasdaq Stock Market, where they have traded in a 52-week range of $7.33 to $33.45.

In a pilot study of 24 volunteer human subjects, Taser said physicians “found no significant cardiac dysrhythmias” immediately after subjects were exposed to an electrical shock from one of its devices. The study evaluated changes in the volunteers’ heart behavior through monitoring activity on an electrocardiogram immediately before and after they were exposed to its Taser X26 gun, the company said.

An abstract of the study was published in a supplemental edition of Academic Emergency Medicine, and the complete study will be presented at the Society of Academic Emergency Medicine in New York starting May 22, Taser said.

Thank you for visiting Spokesman.com. To continue reading this story and enjoying our local journalism please subscribe or log in.

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

Oops, it appears there has been a technical problem. To access this content as intended, please try reloading the page or returning at a later time. Already a Spokesman-Review subscriber? Activate or Log in